Navigation Links
Johnson & Johnson Presents Growth Strategies for Medical Devices & Diagnostics Segment
Date:1/22/2013

NEW YORK, Jan. 22, 2013 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will present its Medical Devices & Diagnostics (MD&D) business strategy for accelerating growth during its annual Business Review today. The presentations will focus on its market leading products, plans for global expansion and meaningful innovations in MD&D that position the company well for long-term growth in a dynamic market. Johnson & Johnson last highlighted its MD&D business in 2010.

"Our MD&D business is the largest medical technology business in the world with sales of $27.4 billion, which grew 8.7% operationally with the inclusion of Synthes," Alex Gorsky , Chairman and Chief Executive Officer, said. "We're building on our market leadership positions, having sustained or grown share in the majority of our key platforms, and hold number one or number two positions in over 80% of them today. We're also expanding our MD&D business in emerging markets, and with Synthes, generated strong double-digit growth there last year."

MD&D accounted for about 41% of Johnson & Johnson's total sales in 2012. Its businesses are global leaders with strong market positions across a broad range of areas, including orthopaedics, neurosurgery, general surgery, vision care, diabetes care, infection prevention, cardiovascular and aesthetics.

In the last two years, the company has invested approximately $3.5 billion in research and development for its MD&D segment, advancing its pipelines and developing new technologies and solutions across its businesses. It has also made decisions to shape its portfolio, including completing the approximately $20 billion acquisition of Synthes, Inc.--the largest acquisition in Johnson & Johnson history, while also continuing to take a disciplined approach to adapting its businesses to reflect the evolving needs of the marketplace."


'/>"/>
SOURCE Johnson & Johnson
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Alliqua Names David Johnson Executive Chairman of Aquamed Technologies and Member of Alliqua Board of Directors
2. Janssen and Johnson & Johnson to Provide Webcast Presentation of Immunology Pivotal Phase 3 Data Being Presented at the American College of Rheumatology Annual Meeting
3. Johnson & Johnson Postpones Medical Devices & Diagnostics Review
4. Johnson & Johnson to Host Medical Devices & Diagnostics Review
5. Johnson & Johnson Announces Plans to Establish Innovation Centers
6. Robert G. Savage, Former Worldwide Chairman, Johnson & Johnsons Pharmaceuticals Group, Joins Board of Nuovo Biologics, LLC
7. Johnson Health Tech Statement on Lance Armstrong
8. EFJohnson Announces Impact Partner Dealer Program
9. Johnson & Johnson Announces Discontinuation of Phase 3 Development of Bapineuzumab Intravenous (IV) in Mild-to-Moderate Alzheimers Disease
10. Johnson & Johnson Provides Notice Of Proposed Settlement Of Shareholder Derivative Actions, Final Settlement Hearing, And Right To Appear
11. GHX CEO Bruce Johnson Recognized as Ernst & Young Rocky Mountain Region Entrepreneur of the Year 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... SAN FRANCISCO , June 29, ... company,s novel blood-draw technology has received CE Mark ... quality from the European Union. This regulatory milestone ... alternative to one of the most common procedures ... Velano Vascular,s proprietary device reduces the ...
(Date:6/29/2015)... , June 29, 2015 ... and predicted revenues ,Where is the market for dermatological ... market? Visiongain ,s new report shows you potential ... and prospects. Our 310 page report ... most lucrative areas in the industry and the future ...
(Date:6/29/2015)... Calif. , June 29, 2015  The ... innovative features to cars on the basis of ... The industry is now on the verge of ... cars. While automotive HWW non-critical features such as ... be present in 30 to 40 percent of ...
Breaking Medicine Technology:Velano Vascular Receives CE Mark For Novel Blood Draw Technology Designed to Reduce Needle Exposures for Hospitalized Patients and Healthcare Providers 2Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 2Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 3Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 4Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 5Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 6Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 7Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 8Convergence Trends See the Automotive Industry Integrate Health, Wellness and Wellbeing into Vehicles 2Convergence Trends See the Automotive Industry Integrate Health, Wellness and Wellbeing into Vehicles 3Convergence Trends See the Automotive Industry Integrate Health, Wellness and Wellbeing into Vehicles 4
... Expected in November 2008, BOTHELL, Wash., Oct. 9 ... the completion of patient enrollment and dosing,for the third ... and,efficacy of its formulation of 12-hour extended-release (ER) ibuprofen ... top-line,results from this pivotal trial in November 2008. Ibuprofen ...
... Will Reduce Animal Use in Cosmetics and Chemicals ... Corp. today announced,that results of a recently completed ... EpiDerm in vitro human skin tissue,equivalent. The test ... to be accepted as a validated alternative to ...
Cached Medicine Technology:SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen 2SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen 3MatTek's EpiDerm In Vitro Tissues Headed for Validation in Europe 2
(Date:6/29/2015)... ... June 29, 2015 , ... World Patent Marketing, ... Diaper, a baby invention that makes parenthood less tiring without sacrificing your child's ... market value of USD 52.2 billion in 2017," says Scott Cooper, CEO and ...
(Date:6/29/2015)... Wethersfield, CT (PRWEB) , ... June 29, 2015 ... ... their centers recognized by the independent auditor of customer service for the 40-center ... of more than 1,100 skilled nursing centers in the United States in one ...
(Date:6/29/2015)... ... June 29, 2015 , ... Scientists from the Icahn School ... complete genomes by combining high-throughput DNA sequencing with genome mapping. The methodology enabled ... with human disease, but previously difficult to detect. The study was published today ...
(Date:6/29/2015)... ... ... With Urgent Care Medicine now serving a vital role in our health ... Medicine and the Medical Society of Delaware to provide its latest professional development resource ... professionals. , According to Matthew Bader, Exam Master CEO and President, “This resource is ...
(Date:6/29/2015)... ... June 29, 2015 , ... USA Today reported on ... Dakota, Arkansas, and Alabama. To impact the rest of the nation’s growing overdose death ... suggested the following guidelines be followed to stop the increasing overdose trend from continuing: ...
Breaking Medicine News(10 mins):Health News:Bringing Up Baby...Millenials Should Check World Patent Marketing's New Baby Invention 2Health News:Bringing Up Baby...Millenials Should Check World Patent Marketing's New Baby Invention 3Health News:Bringing Up Baby...Millenials Should Check World Patent Marketing's New Baby Invention 4Health News:Bringing Up Baby...Millenials Should Check World Patent Marketing's New Baby Invention 5Health News:National HealthCare Centers Receive 'Customer Experience Awards' 2Health News:National HealthCare Centers Receive 'Customer Experience Awards' 3Health News:National HealthCare Centers Receive 'Customer Experience Awards' 4Health News:Mount Sinai Scientists Develop New Approach for More Accurate and Comprehensive Whole Genome Assembly, Variant Discovery and Interpretation 2Health News:Mount Sinai Scientists Develop New Approach for More Accurate and Comprehensive Whole Genome Assembly, Variant Discovery and Interpretation 3Health News:Mount Sinai Scientists Develop New Approach for More Accurate and Comprehensive Whole Genome Assembly, Variant Discovery and Interpretation 4Health News:Exam Master Partners to Provide New Urgent Care Continuing Medical Education Resource 2Health News:Exam Master Partners to Provide New Urgent Care Continuing Medical Education Resource 3Health News:Overdose Death Rates Decreased in Florida as of 2015 2Health News:Overdose Death Rates Decreased in Florida as of 2015 3
... colon and rectum, is a common cause of mortality ... caused by colorectal cancer is increasing in both men ... that regulate the cell,s activity. Understanding the differential ... will lead to a better understanding of the development ...
... announces today that TWAS has received the 2010 Premio ... that have made outstanding contributions to knowledge or to ... referred to as Italy,s Nobel prize. TWAS, as ... recognized for its "unprecedented accomplishments of high moral and ...
... Medicine has received a $5.3 million grant from the National ... trial to show the effects of weight loss and increased ... conditions in overweight breast cancer survivors. ,This trial is ... will examine the effect of weight loss on recurrence risk ...
... in 1968 has reached 3,000 consults from transplantation ... The University of Cincinnati (UC) transplant team with ... made the 3,000th consult late last week to ... experiencing a post-transplant lymphoproliferative disorder. IPITTR is ...
... BOSTON -- The central dogma of molecular biology, as proposed in ... is transferred from DNA to functional proteins by way of messenger ... that being to encode for proteins. Now, a cancer genetics ... much more to RNA than meets the eye. In ...
... assessing patients after cardiac arrest may be underestimating their ... new study by University of Pittsburgh School of Medicine ... . "The care of cardiac arrest patients has ... C. Rittenberger, M.D., M.S., assistant professor of emergency medicine ...
Cached Medicine News:Health News:Hydrophobic proteins: Potential biomarkers for colorectal cancer 2Health News:TWAS awarded Premio Feltrinelli 2Health News:UC San Diego researcher awarded $5.3 million for breast cancer survivorship study 2Health News:Israel Penn Registry marks 3,000 consults for transplant care providers 2Health News:The language of RNA decoded: Study reveals new function for pseudogenes and noncoding RNAs 2Health News:The language of RNA decoded: Study reveals new function for pseudogenes and noncoding RNAs 3Health News:Traditional neurologic exams inadequate for predicting survival of cardiac arrest patients 2
... A concentrated enzymatic cleanser ... semi-automated hematology instruments. It ... all Abbott CELL-DYN® hematology ... instruments. The shelf life ...
Streck-CD3500 Hemoglobin/Lyse is a lytic reagent for the quantitative determination of hemoglobin on the Abbott CELL-DYN® 3500 and 3700. The shelf life is two years from the date of manufacture....
Streck-Diluent III Plus is a balanced electrolyte solution manufactured specifically for use as a diluent for blood cell counting and sizing on the Abbott CELL-DYN® 3000, 3500 and 3700. The shelf...
Streck-Diluent IIIA is a balanced electrolyte solution manufactured specifically for use as a diluent for blood cell counting and sizing on the Abbott CELL-DYN® 1700. The shelf life is one year f...
Medicine Products: